4th Quarter - Report

SOCIETY FOR MATERNAL-FETAL MEDICINE for SOCIETY FOR MATERNAL-FETAL MEDICINE

Firm
Client
Income
—
Expenses
$10,000
Expense method
B: tax-exempt organisations, Internal Revenue Code section 6033(b)(8)

What was lobbied

2 issue areas, each in the filer's own words, with who lobbied on it and where.

Budget/Appropriations BUD

FY 2025 and FY 2026 funding for the National Institutes of Health, the Centers for Disease Control and Prevention, the Agency for Healthcare Research & Quality, and the Health Resources and Services Administration

LobbyistCovered position, as disclosed
REBECCA ABBOTT New —

Contacted: HOUSE OF REPRESENTATIVES; Health Resources & Services Administration (HRSA); SENATE; Natl Institutes of Health (NIH); Centers For Disease Control & Prevention (CDC); Agency for Healthcare Research & Quality (AHRQ)

Health Issues HCR

inclusion of pregnant and lactating women in clinical trials, federal support for maternal mortality review committees and perinatal quality collaboratives

LobbyistCovered position, as disclosed
REBECCA ABBOTT New —

Contacted: Centers For Medicare and Medicaid Services (CMS); Centers For Disease Control & Prevention (CDC); Health & Human Services, Dept of (HHS); SENATE; Health Resources & Services Administration (HRSA); Agency for Healthcare Research & Quality (AHRQ); HOUSE OF REPRESENTATIVES; Natl Institutes of Health (NIH); Food & Drug Administration (FDA)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.